高级检索
当前位置: 首页 > 详情页

p-Hydroxylcinnamaldehyde slows the progression of 4NQO-induced oesophageal tumourigenesis via the RhoA-MAPK signaling pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China [2]Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China
出处:
ISSN:

关键词: immune regulation oesophageal squamous cell carcinoma (ESCC) p-Hydroxylcinnamaldehyde (CMSP) preneoplastic lesion

摘要:
p-Hydroxylcinnamaldehyde isolated from the Cochinchina momordica seed (CMSP) has been identified to inhibit growth and metastasis in oesophageal squamous cell carcinoma (ESCC) by inducing differentiation. The aim of the present study was to evaluate the effect and underlying mechanism of CMSP on 4-nitroquinoline 1-oxide (4NQO)-induced oesophageal tumourigenesis. In the present study, a mouse model of oesophageal preneoplastic lesions was established by providing 4NQO-containing drinking water to C57BL/6 mice. The effect of CMSP on tumourigenesis induced by the chemical mutagen and the effect of CMSP on immune function were investigated. The results showed that the incidence and pathological stage of atypical hyperplasia in oesophageal tissues were significantly reduced in CMSP-treated mice compared with untreated mice. Immunohistochemistry and pull-down assay results revealed that the expression levels of p-ERK1/2, p-SAPK/JNK, and GTP-RhoA were significantly decreased in the oesophageal tissue of CMSP-treated mice. In addition, the proportions of CD4(+) T cells, CD8(+) T cells, and NK cells were increased, while the proportion of CD4(+) CD25(+) regulatory T cells (Tregs) was decreased, in the peripheral blood of CMSP-treated mice. These results indicated that CMSP could hamper 4NQO-induced oesophageal tumourigenesis by regulating the RhoA-ERK/JNK signaling pathway and promoting immune system function, thus providing a new potential strategy for treating preneoplastic lesions of the oesophagus.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 2 区 生化与分子生物学 3 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 生化与分子生物学 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q2 ONCOLOGY Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2023]版:
Q2 ONCOLOGY Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China
共同第一作者:
通讯作者:
通讯机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China [*1]Research Center, The Fourth Hospital of Hebei Medical University, 12# Jiankang Road, Shijiazhuang, Hebei 050011, PR China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号